



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Batra et al.

Serial No.: 09/894,921

Docket No.: 20243CA

Filed: June 28, 2001

For: "COMPRESSED TABLET FORMULATION"

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Examiner:
Sharareh, Shahnam I.

Art Unit:
1617

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 11-10-03
EXPRESS MAIL NO. CV323152342US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY h. p. Scheider
DATE Nov 10 2003

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with 37 C.F.R. 1.97, submitted herewith on the attached form is a list of patents, publications, or other information. Copies of the cited references are enclosed. The submission and listing of these references is not to be construed as an admission that any of the submitted references is "prior art" with respect to the claimed invention. In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

Each item of information contained herein was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months before the filing of this information disclosure statement. The following are comments on three of documents in the attached list:

1. Document D3 is in Spanish, but translations of selected parts of the text are in parentheses. The document discloses certain HIV-1 protease inhibitors (especially saquinavir, ritonavir, indinavir and nelfinavir), and provides a brief discussion of clinical studies, resistance, adverse effects and metabolism. There is no mention of efavirenz. This document has essentially no relevance to the claimed subject matter.
2. Document D4 is also in Spanish, but translations of selected parts of the text are in parentheses. The document lists the principal groups of HIV antivirals

including efavirenz. This document has essentially no relevance to the claimed subject matter.

3. Document D5 is a portion of a 1995 edition of Remington's Pharmaceutical Sciences. Pages 859-863 closely correspond to Remington's Pharmaceutical Sciences, 19th edition, 1995, pp. 1616-1620, which is already of record. Pages 865-869 of Document C provide a general description of granulation methods. This document provides general technical information of interest as background with respect to the claimed invention, but is not otherwise relevant.

It is requested that the Examiner consider the cited references as part of the examination of the subject application, make the references of record, and return an initialed copy of the attached form with the next communication to Applicants.

Since this statement is being filed before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. 1.114, no fee is believed to be due.

Respectfully submitted,

By: Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants
MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Date: November 10, 2003

COMPLE. IF KNOWN

Application Number	09/894,921
Filing Date	June 28, 2003
First Named Inventor	Batra et al.
Group Art Unit	1617
Examiner Name	Sharareh, Shahnam J.
Attorney Docket Number	20243CA

Sheet

1

of

2

Attorney Docket Number

20243CA

[illegible][illegible]Date
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

PIPE
APPLICANT
MAR 18 2004
PATENT & TRADEMARK OFFICE
of 2

COMPL. & IF KNOWN

Application Number	09/894,921
Filing Date	June 28, 2003
First Named Inventor	Batra et al.
Group Art Unit	1617
Examiner Name	Sharareh, Shahnam J.
Attorney Docket Number	20243CA

Sheet	2	of
-------	---	----

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
-----------------------	------------	--

D3.	"Los Inhibidores de La Proteasa Del VIH-1", 1997, http://www.prevenir.com/salud/sida/inhibid-proteasa.html .
D4.	"Tratamiento con Antirretrovirales" , 1997, http://www.prevenir.com/salud/sida/tratamiento.html .
D5.	Remington's Pharmaceutical Sciences, 1995, pp. 859-869.
D6.	L.M. Prescott, "Antimicrobial Agents and Chemotherapy" , 1997, Vol. X, No. 12 , http://thebody.com/bp/dec97/anti.html .

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY
Kenneth R. Walton

DATE
11/10/2003

CASE NUMBER/
20243CA

SERIAL NUMBER
09/894,921


DATE FILED
June 28, 2001

APPLICANT
Batra et al.

EXPRESS MAIL NO.
EV 323152342 US

The Patent & Trademark Office acknowledges and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET



F4424